Immunoscore® included in ESMO Clinical Practice Guidelines 2020

Marseille, France, August 06, 2020. HalioDx SAS, the immuno-oncology diagnostic company, today announced
that Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical
Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer.

In these guidelines, Immunoscore® is considered for its ability to refine the prognosis of early colon cancer
patients, in conjunction with the TNM1 scoring and thus to adjust the chemotherapy decision-making process in
stage II and in low-risk stage III patients.

These guidelines complement the WHO (IARC) introduction of immune response as an important element of risk
assessment for colorectal cancer, in addition to traditional histologic parameters.

“With increasing accuracy in patient’s risk of recurrence, precision medicine substantially improves therapeutic
strategies”, said Pr. Josep Tabernero, from Barcelona, Director of Vall d’Hebron Institute of Oncology (VHIO)
and co-author of guidelines. “Immunoscore® can be helpful to adjust the chemotherapy decision, notably when
we have choices to make between quality of life and risk of relapse”.

“We are pleased that ESMO recognizes the extensive clinical validation of Immunoscore® in localised Colon cancer
and consider it a significant milestone in our strategy to facilitate access to Immunoscore® testing through patient
assistance programs and reimbursement initiatives”, said Vincent Fert, CEO of HalioDx.

The ESMO Guidelines are updated regularly to ensure the inclusion of the latest and most effective practices.

 

About Immunoscore®

Immunoscore® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides
a robust, precise, and quantitative assessment of lymphocytic infiltration and has been shown to predict
outcome and response to therapies in several indications. Immunoscore® is currently being investigated in a
broad number of clinical studies and cancer indications for establishing its performances as a prognostic factor
as well as a predictive factor for response to drugs, notably chemotherapies and immunotherapies.

Immunoscore® Colon is the first IVD diagnostic test of our Immunoscore® portfolio for which a comprehensive
corpus of clinical data demonstrating its clinical utility associated with TNM scoring in the management of
localised colon cancer has been published. Additional immune-based assays in the same portfolio are used as
clinical trial assays to support translational research and clinical development. Those assays enable Multiplex
Spatial Tissue Analysis and combine proprietary multiplexed immunohistochemistry, advanced image analysis
and computerized algorithms.

Immunoscore® is commercially available in more than 20 countries.

 

About HalioDx

The Immune Response to Cancer Diagnostics
HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations
with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to
precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring
solutions including its flagship Immunoscore® assay for the assessment of the immune contexture of a tumor,
as a key determinant of patients’ outcomes and response to cancer treatments.

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant
biomarker signatures, the demonstration of their clinical utility in trials and the development and
commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise
and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a
world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in
Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx
has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines,
chemotherapies, oncolytic peptides, and CAR-T cell therapies.

For more information, please visit our websites www.haliodx.com and www.immunoscorecolon.com and follow the company on Twitter, Linkedin and Youtube.

Immunoscore® is a registered trademark of Inserm licenced to HalioDx. Brightplex®, TMExplore™ and
Immunosign® are registered trademarks of HalioDx.

 

Contacts : 

Vincent Fert
President and CEO
+ 33 (0)4 91 29 30 90
vincent.fert@haliodx.com

ATCG Partners
Marie Puvieux / Céline Voisin
+33 (0)9 81 87 46 72 / +33 (0)6 62 12 53 39
haliodx@atcg-partners.com

Publié dans la catégorie in